Indoco Remedies Ltd. announces final approval from the United States Food & Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg, and 200 mg, the generic version of Vimpat Tablets of UCB, Inc.

Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug.

Commenting on the development, Ms. Aditi Kare Panandikar, Managing Director-Indoco Remedies said, “The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates our enduring commitment to making quality and affordable generic medicines available to more patients in the United States. Our first shipment of Lacosamide Tablets has already reached the US”.

According to IQVIA sales data for the period ending January 2022, the Vimpat Tablets market achieved annual sales of approx. USD 1.7 billion.

Indoco Remedies is currently trading at Rs 417.60 up by Rs8.05 or 1.97% from its previous closing of Rs 409.55 on the BSE. The scrip opened at Rs419 and has touched an intraday high and low of Rs 426 and Rs 402 respectively.